« Zurück
Startseite /
KCTD11 (potassium channel tetramerisation domain containing 11)

KCTD11 (potassium channel tetramerisation domain containing 11)

ArtNr	18-003-43897
Hersteller	GENWAY
Menge	0.1 mg
Kategorie	Oncology Antibodies Western Blot Cardiovascular Research Ischemia & Reperfusion Injury Primary Antibodies By Organ Brain Cancer
Typ	Antibody
Applikationen	WB
Specific against	other
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Alias	GWB-D82207
Similar products	18-003-43897
Lieferbar
Genway ID:	GWB-D82207
Antigen Specificity:	Polyclonal antibody produced in rabbits immunized with a synthetic peptide corresponding to a region of Human KCTD11.
ELISA Titre:	1:62500
Note:	Suggested starting concentrations are provided. Optimal dilutions should be determined by end-user. Differences in calculated versus apparent molecular weight may be due to post-translational modifications or protein hydrophobicity. The KCTD11 gene encodes a protein that has been identified as a suppressor of Hedgehog signaling. Its inactivation might lead to a deregulation of the tumor-promoting Hedgehog pathway in medulloblastoma.
Function:	Play a role as a marker and a regulator of neuronal differentiation; Up-regulated by a variety of neurogenic signals such as retinoic acid epidermal growth factor/EGF and NGFB/nerve growth factor. Induces apoptosis growth arrest and the expression of cyclin-dependent kinase inhibitor CDKN1B. Plays a role as a tumor repressor and inhibits cell growth and tumorigenicity of medulloblastoma (MDB). Functions as antagonist of the Hedgehog pathway on cell proliferation and differentiation by affecting the nuclear transfer of transcrition factor GLI1 thus maintaining cerebellar granule cells in undifferentiated state. When knock-down Hedgehog antagonism is impaired and proliferation of granule cells is sustained. Activates the caspase cascade.
Tissue Specificity:	Higher expression in cerebellum than in whole brain and lower expression in medulloblastoma.
Domain:	The BTB domain is required for growth-suppressing properties.
Disease:	Haploinsufficiency of KCTD11 may be a cause of development of medulloblastoma (MDB). MDB is a malignant invasive embryonal tumor of the cerebellum with a preferential manifestation in children. An allelic deletion involving genes from chromosome region 17p11. 2-pter sometimes restricted to 17p13. 2-13. 3 occurs in up to 50% of MDB.
Similarity:	Contains 1 BTB (POZ) domain. Di (2004) Proc. Natl. Acad. Sci. U. S. A. 101 (29). 10833-10838.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

Sicherheitsdatenblatt anfordern

Einfache Bestellung Periodische Bestellung

Menge: 0.1 mg

lieferbar

Lieferung vsl. bis 11.09.2025

Express-Lieferung: 7 Tage sparen

Vergleichen

Auf den Wunschzettel

Angebot anfordern